Cingulate was issued a European patent for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder. The patent application was granted on August 14, 2024, as EP Patent No. 3261625, and will include up to 30 European territories, including the United Kingdom. In addition to the European patent, Cingulate has patents in Australia, Canada and Israel, as well as pending patents in Hong Kong, the Republic of Korea, and the United States.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
- Cingulate sees cash runway late into 3Q24
- Cingulate reports Q2 EPS ($5.47) vs. ($6.79) last year
- Cingulate Inc trading halted, news pending
- Cingulate files to sell 6.63M shares of common stock for holders